GuidelineSchmerz (Berlin, Germany)2008
[Pharmacological treatment of fibromyalgia syndrome].
Guideline in Schmerz (Berlin, Germany), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.
- [Methodology of the development of the updated LONTS guidelines for long-term administration of opioids in noncancer pain].Schmerz (Berlin, Germany) · 2015Pooled it
- [Drug therapy of fibromyalgia syndrome. Systematic review, meta-analysis and guideline].Schmerz (Berlin, Germany) · 2012Guideline
- Systematic review and network meta-analysis of interventions for fibromyalgia: a protocol.Systematic reviews · 2013Article
- [Treatment and healthcare costs of fibromyalgia syndrome in Germany: analysis of the data of the Barmer health insurance (BEK) from 2008-2009].Schmerz (Berlin, Germany) · 2011Article
- Fibromyalgia: from pathophysiology to therapy.Nature reviews. Rheumatology · 2011Review
- [Fibromyalgia--the new guideline].Zeitschrift fur Rheumatologie · 2009Review
- Fibromyalgia syndrome: classification, diagnosis, and treatment.Deutsches Arzteblatt international · 2009Article
- [Visualization of a myth--the new S3 guidelines for fibromyalgia syndrome].Schmerz (Berlin, Germany) · 2009Article
- Management of fibromyalgia syndrome--an interdisciplinary evidence-based guideline.German medical science : GMS e-journal · 2008Article
- [Is the dilemma of fibromyalgia solved by the guideline?].Schmerz (Berlin, Germany) · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAn interdisciplinary guideline for the treatment of fibromyalgia syndrome (FMS) and chronic widespread pain (CWP) was developed in cooperation with ten German medical and psychological associations and two patients' self-help organizations.
methodsUsing the Cochrane Collaboration Reviews (1993-12/2006), Medline (1980-2006), PsychInfo (1966-12/2006), and Scopus (1980-12/ 2006) a systematic literature search was performed, which included all randomised controlled trials (RCT) evaluating multicomponent therapy in FMS and CWP. Levels of evidence were assigned according to the classification system of the Oxford Centre for Evidence-Based Medicine. The strength of recommendation was graded according to the German program for disease management guidelines. Consensus was achieved using a multi-step nominal group procedure.
resultsThe short-term use of amitriptyline is strongly recommended (grade A) and the short-term use of fluoxetine und duloxetine is recommended (grade B).
conclusionsThe recommendations regarding pharmacological treatment of FMS are limited by the short duration of the RCT, the lack of follow-ups and absence of cost-effectiveness studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.